Adage Capital Partners’s F-star Therapeutics, Inc. Common Stock FSTX Stock Holding History

Adage Capital Partners’s Portfolio FSTX Stock Details FSTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-900,000	Closed	-$3.19M	–	1172
2022 Q1	$3.19M	Hold	900,000	–	–	0.01%	870
2021 Q4	$4.52M	Hold	900,000	–	–	0.01%	824
2021 Q3	$6.59M	Buy	900,000 +100,000	+13%	+$686K	0.01%	798
2021 Q2	$6.87M	Buy	+800,000	New	+$6.82M	0.01%	776
2019 Q4	–	Sell	-356,250	Closed	-$4.9M	–	776
2019 Q3	$4.9M	Hold	356,250	–	–	0.01%	627
2019 Q2	$5.26M	Buy	356,250 +106,250	+43%	+$2.85M	0.01%	603
2019 Q1	$10.5M	Hold	250,000	–	–	0.03%	519
2018 Q4	$10.4M	Buy	250,000 +62,500	+33%	+$2.81M	0.03%	501
2018 Q3	$9.04M	Buy	187,500 +162,500	+650%	+$8.14M	0.02%	560
2018 Q2	$1.19M	Hold	25,000	–	–	﹤0.01%	705
2018 Q1	$1.54M	Buy	+25,000	New	+$1.32M	﹤0.01%	678

Other funds holding FSTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

AVA

Atlas Venture Advisors Boston, Massachusetts $143M AUM 25.68% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Adage Capital Partners's FSTX Position: Q2 2022 in Review

Adage Capital Partners sold out of F-star Therapeutics, Inc. Common Stock (FSTX) in Q2 2022, closing a stake of 900,000 shares — an estimated $3.19M sold.

Adage Capital Partners first reported a position in FSTX in Q1 2018 and held it in 11 quarters. The position peaked at $10.5M in Q1 2019. 53 funds tracked by Wall St. Rank hold FSTX as of Q2 2022.

Adage Capital Partners reported no remaining F-star Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Adage Capital Partners sold 900,000 F-star Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $3.19M.
Adage Capital Partners first reported a position in F-star Therapeutics, Inc. Common Stock in Q1 2018 and held it in 11 quarters.
Adage Capital Partners's F-star Therapeutics, Inc. Common Stock position peaked at $10.5M in Q1 2019.
53 funds tracked by Wall St. Rank held F-star Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Adage Capital Partners's 13F filing for Q2 2022, filed 15 Aug 2022.